Gyomor- és nyelőcsőrák: vizsgálatok itt: Argentína
6 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- ABB, Buenos Aires, Ciudad Autónoma de Buenos Aires
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Buenos Aires, Caba, Ciudad Autonoma Buenos Aires, Mar del Plata
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Buenos Aires, Ciudad Autónoma Buenos Aires, Ciudad de Buenos Aires, Rosario, Viedma
- Életkor
- 18 év and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - 3. fázisTaking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- CABA, Ciudad Autonoma Buenos Aires, La Rioja
- Életkor
- 18 év and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - 3. fázisTaking peopleStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Where
- Buenos Aires, Córdoba, Mar del Plata, Rosario
- Életkor
- 18 év and over
- People
- 726 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06731478 - 3. fázisTaking peopleA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Where
- Buenos Aires, Cordoba, Córdoba, Puerto Alegre, Rosario, San Juan, San Miguel de Tucumán, San Pablo, Viedma
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06532006 · EU 2024-516633-12-00